BioAlliance Pharma in-licenses new pipeline project
Paris – BioAlliancePharma has filled its early-stage pipeline with Odansentron. The 5-HT3 compound is already marketed as a tablet, and now BioAlliance is planning to develop it as a mouth spray. “This fits well into our strategy to expand our presence in supportive care for oncology patients, and to focus on patient convenience,” company CEO Dominique Constantini told EuroBiotechNews. BioAlliance paid US$3m for the European rights for the Odansentron spray in advance to US-based NovaDel Pharma Inc. The out-licensor is also eligible for milestones potentially amounting to US$24m. BioAlliance’s responsibility will be to bring the product to market in Europe. In the US, NovaDel’s partner Par Pharmaceutical is responsible for the clinical development and the US registration. BioAlliance will use these documents for the European application. Par and BioAlliance are already cooperating on Loramyc, which is a novel miconazole lozenge-formulation against oral candidiasis.
The Euronext-listed BioAlliance focuses on specialty pharma products sold in the hospital. The company launched Loramyc last year in cooperation with Dutch Spe-pharm in Europe. BioAlliance is running two Phase III trials with Acyclovir, a tablet against labial herpes, and with a new formulation of Doxorubicin. To overcome resistance issues, the approved chemotherapeutic was formulated with nanoparticles and masked by sugar residues. BioAlliance pharma has EUR56m in the bank, and is currently burning almost EUR20m per year. In 2012, the company aims to have four products on the market.